Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC — Stella

Home/Head and Neck Squamous Cell Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Head and Neck Squamous Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

National Cancer Cencer/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~173 participants

Started

December 2023

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated December 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.